Clarivate to Sell Life-sciences, Healthcare Segment to Altaris for $600 Million

Dow Jones

07/06

Clarivate inked a deal to sell its life-sciences and healthcare segment to investment firm Altaris for $600 million.

Clarivate on Monday said the move will allow the London provider of global information, analytics and workflow solutions to focus on AI-driven intelligence for its academia and government and intellectual-property segments.

Clarivate said it will receive $500 million in cash at closing, along with $25 million in cash deferred to the completion of a transition-services agreement and a $75 million seller note, adding that it plans to use the cash proceeds to pare its debt load and bolster its balance sheet.

The company said it expects to complete the sale by the end of the year, and that it expects to book a non-cash goodwill impairment of $225 million to $250 million on the life-sciences and healthcare segment.

Altaris, a New York firm that focuses exclusively on the healthcare industry and manages more than $9 billion of equity capital, last month agreed to buy drug-development company Simulations Plus for around $375 million.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

July 06, 2026 06:28 ET (10:28 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2649623661"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2649623661\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2649623661?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-06 18:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649623661","market":"sh","top_or_hot":-1,"title":"Clarivate to Sell Life-sciences, Healthcare Segment to Altaris for $600 Million","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Clarivate inked a deal to sell its life-sciences and healthcare segment to investment firm Altaris for $600 million. \n</p>\n<p>\n  Clarivate on Monday said the move will allow the London provider of global information, analytics and workflow solutions to focus on AI-driven intelligence for its academia and government and intellectual-property segments. \n</p>\n<p>\n  Clarivate said it will receive $500 million in cash at closing, along with $25 million in cash deferred to the completion of a transition-services agreement and a $75 million seller note, adding that it plans to use the cash proceeds to pare its debt load and bolster its balance sheet. \n</p>\n<p>\n  The company said it expects to complete the sale by the end of the year, and that it expects to book a non-cash goodwill impairment of $225 million to $250 million on the life-sciences and healthcare segment. \n</p>\n<p>\n  Altaris, a New York firm that focuses exclusively on the healthcare industry and manages more than $9 billion of equity capital, last month agreed to buy drug-development company <a href=\"https://laohu8.com/S/SLP\">Simulations Plus</a> for around $375 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 06, 2026 06:28 ET (10:28 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clarivate to Sell Life-sciences, Healthcare Segment to Altaris for $600 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClarivate to Sell Life-sciences, Healthcare Segment to Altaris for $600 Million\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-07-06 18:28</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Clarivate inked a deal to sell its life-sciences and healthcare segment to investment firm Altaris for $600 million. \n</p>\n<p>\n  Clarivate on Monday said the move will allow the London provider of global information, analytics and workflow solutions to focus on AI-driven intelligence for its academia and government and intellectual-property segments. \n</p>\n<p>\n  Clarivate said it will receive $500 million in cash at closing, along with $25 million in cash deferred to the completion of a transition-services agreement and a $75 million seller note, adding that it plans to use the cash proceeds to pare its debt load and bolster its balance sheet. \n</p>\n<p>\n  The company said it expects to complete the sale by the end of the year, and that it expects to book a non-cash goodwill impairment of $225 million to $250 million on the life-sciences and healthcare segment. \n</p>\n<p>\n  Altaris, a New York firm that focuses exclusively on the healthcare industry and manages more than $9 billion of equity capital, last month agreed to buy drug-development company <a href=\"https://laohu8.com/S/SLP\">Simulations Plus</a> for around $375 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 06, 2026 06:28 ET (10:28 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XBI","symbol_name":"SPDR S&P Biotech ETF","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2649623661","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649623661","pubTimestamp":1783333680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Clarivate inked a deal to sell its life-sciences and healthcare segment to investment firm Altaris for $600 million.Clarivate on Monday said the move will allow the London provider of global information, analytics and workflow solutions to focus on AI-driven intelligence for its academia and government and intellectual-property segments.Clarivate said it will receive $500 million in cash at closing, along with $25 million in cash deferred to the completion of a transition-services agreement and a $75 million seller note, adding that it plans to use the cash proceeds to pare its debt load and bolster its balance sheet.The company said it expects to complete the sale by the end of the year, and that it expects to book a non-cash goodwill impairment of $225 million to $250 million on the life-sciences and healthcare segment.Altaris, a New York firm that focuses exclusively on the healthcare industry and manages more than $9 billion of equity capital, last month agreed to buy drug-developm","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XBI":"SPDR S&P Biotech ETF","BK4581":"高盛持仓","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","BK4585":"ETF&股票定投概念","CLVT":"Clarivate Plc","XLV":"健康照护类股ETF-SPDR","HCSG":"Healthcare Svcs Group Inc","BK4137":"综合支持服务","LABU":"三倍做多标普生物-Direxion","BK4561":"索罗斯持仓","BK4588":"碎股","BK4123":"调查和咨询服务","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC"},"translate_title":"科睿唯安将以6亿美元将生命科学和医疗保健部门出售给Altaris","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XLV":1.5,"HCSG":1.5,"CLVT":0.9,"LABU":0.6,"XBI":0.6},"content_text":"Clarivate inked a deal to sell its life-sciences and healthcare segment to investment firm Altaris for $600 million. \n\n\n  Clarivate on Monday said the move will allow the London provider of global information, analytics and workflow solutions to focus on AI-driven intelligence for its academia and government and intellectual-property segments. \n\n\n  Clarivate said it will receive $500 million in cash at closing, along with $25 million in cash deferred to the completion of a transition-services agreement and a $75 million seller note, adding that it plans to use the cash proceeds to pare its debt load and bolster its balance sheet. \n\n\n  The company said it expects to complete the sale by the end of the year, and that it expects to book a non-cash goodwill impairment of $225 million to $250 million on the life-sciences and healthcare segment. \n\n\n  Altaris, a New York firm that focuses exclusively on the healthcare industry and manages more than $9 billion of equity capital, last month agreed to buy drug-development company Simulations Plus for around $375 million. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 06, 2026 06:28 ET (10:28 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}